Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 600

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 600
---
 Kineta’s inception through December 31, 2024, Kineta’s operations have been financed primarily by net cash proceeds from
the sale and issuance of Kineta Common Stock and borrowings under notes payable. Kineta has also received upfront and milestone payments from Kineta’s license agreements. As of December 31, 2024, Kineta had $634,000 in cash and an
accumulated deficit of $182.9 million. Kineta expects that Kineta’s research and development and general and administrative expenses will increase, and, as a result, anticipate that Kineta will continue to incur increasing losses for the
foreseeable future. Therefore, Kineta will need to raise additional capital to fund Kineta’s operations, which may be through the issuance of additional equity or through borrowings.

In July 2024, Kineta received a $5.0 million exclusivity payment from TuHURA pursuant to the exclusivity and right of first offer
agreement (the “Exclusivity Agreement”) and have entered into the Merger Agreement on December 11, 2024. In October 2024, TuHURA exercised its right to extend the Exclusivity Agreement and paid Kineta $300,000 in Exclusivity Payments.
Under the CTF Agreement, Kineta received cash of $695,000 from TuHURA during the year ended December 31, 2024 to reimburse us for clinical trial expenses. Subsequent to December 31, 2024, Kineta has received cash of $852,000 from TuHURA to
reimburse us for clinical trial expenses and received cash of $250,000 from TuHURA as a loan.

Subsequent to December 31, 2024,
pursuant to a certain exclusivity agreement (“KCP506 Exclusivity Agreement”) dated January 8, 2025, by and between Kineta’s subsidiary, Kineta Chronic Pain and Pacira, Kineta received from Pacira a non-refundable and
non-creditable exclusivity payment of $50,000 in cash. On February 4, 2025, Kineta Chronic Pain entered into an asset purchase agreement with Pacira pursuant to which Kineta Chronic Pain agreed to sell certain of its assets related to the
development of KCP506, a product candidate for pain treatment. In return, Pacira agreed to pay a purchase price of $450,000 and assume limited liabilities associated with the KCP506 assets. Pacira also